With human clinical trials underway, it’s hoped the virus, which has not only been engineered to make cancer cells more recognisable to the body’s immune system but to also harm them, will help people with cancer respond to the disease more effectively.
Scientists have warned that results seen in animal tests do not always translate to humans, but they are hopeful that it will be the case.
Phase 1 of the trial will see 100 cancer patients injected with the virus. Each of these patients has metastatic or advanced solid tumours and has previously tried at least two other treatments.
The patients will be split into two groups – one will receive the Vaxinia injection alone and the other will get the Vaxinia injection alongside another immunotherapy drug.
While the trial isn’t expected to be complete until early 2025, it’s an exciting next step in finding effective cancer treatments.
Have your say in our news democracy. Click the upvote icon at the top of the page to help raise this article through the indy100 rankings.